Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART)

Journal of the Medical Association of Thailand

Volumn 88, Issue 7, 2005, Pages 956-966

  Lapphra, Keswadee ^a   Vanprapar, Niran ^a   Phongsamart, Wanatpreeya ^a   Chearskul, Pimpanada ^a   Chokephaibulkit, Kulkanya ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Children; Dyslipidemia; HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; INDINAVIR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ARTICLE; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DEVELOPING COUNTRY; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIPID BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE COUNT; MALE; PERIPHERAL LIPOATROPHY; RISK FACTOR; THAILAND;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; LIPODYSTROPHY; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RISK FACTORS; THAILAND;

EID: 25144522613     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998; 12: 167-73.
2. Carr A, Cooper DA. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998; 339: 1296.
3. Vigoureux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, et al. Diabetes, insulin resistance and dyslipidemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999; 25: 225-32.
4. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100: 700-5.
5. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-9.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: 51-8.
7. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal fat accumulation associated with the use of indinavir. Lancet 1998; 351: 871-5.
8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of lipodystrophy, hyperlipidemia and diabetes mellitus. Lancet 1999; 353: 2093-9.
9. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance and beta cell function and lipid metabolism in HIV-patients under treatment with protease inhibitors. AIDS 1999; 13: 63-70.
10. Moyle GJ, Baldwin C. Lipid elevations during non-nucleoside RTI (NNRTI) therapy: a cross sectional analysis. Antiviral Ther 1999; 4: 58.
11. Behrens GM, Meyer-olson D, Stoll M, Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003; 17: 149-54.
12. Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: results from DAD study. AIDS 2003; 17: 1179-93.
13. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
14. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS 1999; 13: 735-7.
15. Passalaris D, Sepkowitz A, Glesby J. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31: 787-97.
16. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001; 15: 847-55.
17. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17: 141-8.
18. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123-8.
19. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 405-10.
20. Lainka E, Oezbek s, Falck M. Marked dyslipidemia in human immunodeficiency virus infected children on protease inhibitor-containing antiretrovirus therapy. Pediatrics 2002; 110: 1-7.
21. Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003; 32: 482-9.
22. Leonard EG, Mc Comsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003; 22: 77-84.
23. Executive Summary, "Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)". JAMA 2001; 285: 2486-513.
24. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children < 13 years of age. MMWR 1994; 43 (RR-12): 1-19.
25. Savès M, Chêne G, Ducimetière P, Leport C, Le Moal G, Amouyel P. Distribution of cardiovascular risk factors in French HIV-infected men started on a protease inhibitor-containing regimen compared to the general population. Antivir Ther 2001; 6: 74.
26. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-52.
27. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86: 27-31.
28. Sherer R. HIV, HAART, and hyperlipidemia: balancing the effects. J Acquir Immune Defic Syndr 2003; 34: 123-9.
29. Farley J, Gona P, Crain M. Hypercholesterolemia and associated risk factors among perinatally HIV infected children (4-19 years) in PACTG219C. 10th Conference of Retroviruses and Opportunistic Infections, Boston, MA, USA2003 (Abstract 773).
30. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 1396-405.
31. Green ML. Evaluation and management of dyslipidemia in patient with HIV infection. J Gen Intern Med 2002; 17: 797-810.
32. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS 2001; 12: 463-8.
33. Kamin D, Hadican C. Hyperlipidemia in children with HIV infection: an emerging problem. Expert Rev Cardiovasc Ther 2003; 1: 143-50.
34. Calza L, Manfredi R, Chiodo F. Hyperlipidemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003; 22: 89-99.
35. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001; 27: 30-4.
36. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389-98.
37. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14: 37-49.